ATE220677T1 - Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung - Google Patents

Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung

Info

Publication number
ATE220677T1
ATE220677T1 AT94906381T AT94906381T ATE220677T1 AT E220677 T1 ATE220677 T1 AT E220677T1 AT 94906381 T AT94906381 T AT 94906381T AT 94906381 T AT94906381 T AT 94906381T AT E220677 T1 ATE220677 T1 AT E220677T1
Authority
AT
Austria
Prior art keywords
alkyl
suitable substituent
pct
pyrazolotriazines
interleukin
Prior art date
Application number
AT94906381T
Other languages
English (en)
Inventor
Yoshio Kawai
Hitoshi Yamazaki
Hirokazu Tanaka
Teruo Oku
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE220677T1 publication Critical patent/ATE220677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT94906381T 1993-02-26 1994-02-09 Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung ATE220677T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939303993A GB9303993D0 (en) 1993-02-26 1993-02-26 New heterocyclic derivatives
PCT/JP1994/000213 WO1994019350A1 (en) 1993-02-26 1994-02-09 Pyrazolitriazines with interleukin-1 and tumour necrosis factor inhibitory activity

Publications (1)

Publication Number Publication Date
ATE220677T1 true ATE220677T1 (de) 2002-08-15

Family

ID=10731142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94906381T ATE220677T1 (de) 1993-02-26 1994-02-09 Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung

Country Status (20)

Country Link
US (1) US5670503A (de)
EP (1) EP0686156B1 (de)
JP (1) JP3569917B2 (de)
KR (1) KR100313615B1 (de)
CN (1) CN1041929C (de)
AT (1) ATE220677T1 (de)
AU (1) AU681625B2 (de)
CA (1) CA2156919A1 (de)
DE (1) DE69430988T2 (de)
DK (1) DK0686156T3 (de)
ES (1) ES2176235T3 (de)
GB (1) GB9303993D0 (de)
HU (1) HUT70832A (de)
IL (1) IL108562A (de)
MX (1) MX9401408A (de)
PT (1) PT686156E (de)
RU (1) RU2124517C1 (de)
TW (1) TW260669B (de)
WO (1) WO1994019350A1 (de)
ZA (1) ZA94787B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360901A1 (de) 1996-04-25 2003-11-12 Nissan Chemical Industries, Limited 2,3-cyclisch substituierte Derivate des 3-Hydroxyacroleins und 3-Hydroxyacrylsäure als Pestizide
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
PT988301E (pt) 1997-06-12 2006-10-31 Aventis Pharma Ltd Acetais ciclicos de imidazolilo
EP1023066A4 (de) 1997-06-13 2001-05-23 Smithkline Beecham Corp Neue pyrazole- und pyrazoline- substituierte verbindung
BR9814820A (pt) 1997-10-14 2000-10-03 Welfide Corp Compostos de piperazina e seu uso médico
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6599910B1 (en) * 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
WO2001015525A1 (en) * 1999-08-31 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. Organ preservatives
MXPA01007019A (es) * 1999-11-10 2002-09-18 Johnson & Johnson 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
RU2316556C2 (ru) * 2000-11-17 2008-02-10 Бристол-Маерс Сквибб Компани СПОСОБЫ ЛЕЧЕНИЯ СОСТОЯНИЙ, ОБУСЛОВЛЕННЫХ p38 КИНАЗАМИ, И ПИРРОЛОТРИАЗИНОВЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ
EP1345938A1 (de) * 2000-12-28 2003-09-24 Neurocrine Biosciences, Inc. Tricyclische crf-rezeptor-antagonisten
SK287857B6 (sk) * 2001-05-24 2012-01-04 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
US6566357B1 (en) * 2001-09-20 2003-05-20 The Procter & Gamble Co. Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
CA2494700C (en) * 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
DE602004030318D1 (de) * 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE395338T1 (de) 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
AU2006276072A1 (en) * 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US20110195962A1 (en) * 2007-08-16 2011-08-11 Alcon Research, Ltd. Use of multi-pharmacophore compounds to treat nasal disorders
US20090082354A1 (en) * 2007-09-20 2009-03-26 Wyeth Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof
CN101441972B (zh) 2007-11-23 2011-01-26 鸿富锦精密工业（深圳）有限公司 场发射像素管
CN101441969B (zh) 2007-11-23 2010-07-28 清华大学 场发射像素管
EP2402344A1 (de) * 2010-06-29 2012-01-04 Basf Se Pyrazolkondensierte bicyclische Verbindungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502178A (ja) * 1990-12-31 1994-03-10 藤沢薬品工業株式会社 イミダゾトリアジン誘導体
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
EP0686156B1 (de) 2002-07-17
ES2176235T3 (es) 2002-12-01
US5670503A (en) 1997-09-23
AU681625B2 (en) 1997-09-04
IL108562A0 (en) 1994-05-30
PT686156E (pt) 2002-12-31
ZA94787B (en) 1994-09-08
AU6010894A (en) 1994-09-14
CN1120840A (zh) 1996-04-17
RU2124517C1 (ru) 1999-01-10
JPH08507056A (ja) 1996-07-30
EP0686156A1 (de) 1995-12-13
KR100313615B1 (ko) 2002-05-30
DK0686156T3 (da) 2002-11-11
JP3569917B2 (ja) 2004-09-29
HU9402459D0 (en) 1994-11-28
TW260669B (de) 1995-10-21
CN1041929C (zh) 1999-02-03
KR960701055A (ko) 1996-02-24
DE69430988T2 (de) 2002-11-28
DE69430988D1 (de) 2002-08-22
MX9401408A (es) 1994-08-31
CA2156919A1 (en) 1994-09-01
GB9303993D0 (en) 1993-04-14
WO1994019350A1 (en) 1994-09-01
HUT70832A (en) 1995-11-28
IL108562A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
ATE220677T1 (de) Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung
HU9601685D0 (en) 4,5-diaryloxazole derivatives
TW262471B (de)
MX9800577A (es) Derivados de 4,5-diaril oxazol.
FI954609A0 (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
GB9300194D0 (en) Piperazine derivatives
GR3035621T3 (en) New pyrimidone derivatives with antifungal activity
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
GB9602029D0 (en) New heterocyclic compounds
EP0572635A4 (de) Verbindungen met Guanidin Struktur und diese enthaltende pharmazeutische Zusammenstellungen.
IL108258A0 (en) Piperazine derivates, their preparation and pharmaceutical compositions containing them
GB9313330D0 (en) New compound and its preparation
DE69330601D1 (de) Serotoninergische ergolin derivate
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
ATE155791T1 (de) Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE255102T1 (de) Benzothiophenderivate, ihre herstellung und verwendung als urokinase-inhibitoren
DK0544748T3 (da) Spiro cycloalkylbenzen-1, 1-(1,2,3,4-tetrahydroisoquinoliner) med neurobeskyttende egenskaber

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee